The UC Davis School of Medicine is one of only 150 sites taking part in the major clinical trial that led to the federal government’s Emergency Use Authorization (EUA) of the Pfizer BioNTech COVID-19 vaccine in December, which helped pave the way for widespread vaccinations last winter and spring. During the trial’s latest phase, 60 participants here received a third dose of either vaccine or placebo to determine whether a booster is necessary, safe and effective against the original COVID-19 strain and the Delta variant. The ongoing worldwide trial involves 40,000 participants, including 225 over the last year at UC Davis. Principal investigators at the school of medicine include internal medicine chair Timothy E. Albertson, M.D., M.P.H., Ph.D., and Angela Haczku, M.D., Ph.D., associate dean for translational research.
Envisioning new heights for the School of Medicine
Read how the School of Medicine continues to excel through the power of education, research and clinical care
Innovating and partnering for patients
David Lubarsky shares an update on how we’re changing health care as we move ahead on our post-pandemic journey
New older adult clinic
The new clinic is a one-stop location where older adults can receive care from geriatric specialists, while receiving support for their caregivers